Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
December 1, 2003
- Toho: Sales Up 17.4%, Net Profits Up 44.9%
December 1, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
December 1, 2003
- Takeover of Nikken Chemicals to Make Kowa Strengthen Marketing, R&D: President Miwa
December 1, 2003
- Global Standard Drugs to Be Covered by Special Medical Expenditure System during Application
December 1, 2003
- BUSINESS NEWS IN BRIEF
December 1, 2003
- Mutual GMP Recognition Discussed: MOSS Followup Talks
December 1, 2003
- PRESS SEMINAR
December 1, 2003
- Semi-annual Business Results
December 1, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
December 1, 2003
- Mochida: Profits Decline Despite Slight Growth in Pharma Sales
December 1, 2003
- DIAGNOSTIC NEWS IN BRIEF
December 1, 2003
- Fuso: Profits Marked for 1st Time in 3 Years
December 1, 2003
- SEMI-ANNUAL BUSINES RESULTS
December 1, 2003
- Teijin: Sales Up, but Operating Profits Hit by R&D Costs
December 1, 2003
- Hearings on Late-night, Early-morning Drug Sales Held
December 1, 2003
- Sawai: Favorable GE Market Drives Strong Growth in Sales, Profits
December 1, 2003
- OTC NEWS IN BRIEF
December 1, 2003
- Kuraya Sanseido: Sales, Net Profits Up Slightly
December 1, 2003
- PRESS SEMINAR
December 1, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…